Dearfield K L, Auletta A E, Cimino M C, Moore M M
Health Effects Division, U.S. Environmental Protection Agency, Washington, DC 20460.
Mutat Res. 1991 Nov;258(3):259-83. doi: 10.1016/0165-1110(91)90012-k.
This paper provides the rationale and support for the decisions the OPP will make in requiring and reviewing mutagenicity information. The regulatory requirement for mutagenicity testing to support a pesticide registration is found in the 40 CFR Part 158. The guidance as to the specific mutagenicity testing to be performed is found in the OPP's Pesticide Assessment Guidelines, Subdivision F, Hazard Evaluation: Human and Domestic Animals (referred to as the Subdivision F guideline). A revised Subdivision F guideline has been presented that becomes the current guidance for submitters of mutagenicity data to the OPP. The decision to revise the guideline was the result of close examination of the version published in 1982 and the desire to update the guidance based on developments since then and current state-of-the-science. After undergoing Agency and public scrutiny, the revised guideline is to be published in 1991. The revised guideline consists of an initial battery of tests (the Salmonella assay, an in vitro mammalian gene mutation assay and an in vivo cytogenetics assay which may be either a bone marrow assay for chromosomal aberrations or for micronuclei formation) that should provide an adequate initial assessment of the potential mutagenicity of a chemical. Follow-up testing to clarify results from the initial testing may be necessary. After this information as well as all other relevant information is obtained, a weight-of-evidence decision will be made about the possible mutagenicity concern a chemical may present. Testing to pursue qualitative and/or quantitative evidence for assessing heritable risk in relation to human beings will then be considered if a mutagenicity concern exists. This testing may range from tests for evidence of gonadal exposure to dominant lethal testing to quantitative tests such as the specific locus and heritable translocation assays. The mutagenicity assessment will be performed in accordance with the Agency's Mutagenicity Risk Assessment Guidelines. The mutagenicity data would also be used in the weight-of-evidence consideration for the potential carcinogenicity of a chemical in accordance with the Agency's Carcinogen Risk Assessment Guidelines. In instances where there are triggers for carcinogenicity testing, mutagenicity data may be used as one of the triggers after a consideration of available information. It is felt that the revised Subdivision F guideline will provide appropriate, and more specific, guidance concerning the OPP approach to mutagenicity testing for the registration of a pesticide. It also provides a clearer understanding of how the OPP will proceed with its evaluation and decision making concerning the potential heritable effects of a test chemical.(ABSTRACT TRUNCATED AT 400 WORDS)
美国环境保护局农药项目办公室(OPP):本文为OPP在要求和审查致突变性信息时所做的决策提供了依据和支持。支持农药登记的致突变性测试的监管要求载于《联邦法规汇编》第40编第158部分。关于具体要进行的致突变性测试的指南载于OPP的《农药评估指南》F分部,即《危害评估:人类和家畜》(简称F分部指南)。现已出台修订后的F分部指南,成为向OPP提交致突变性数据者的现行指南。修订该指南的决定是在仔细审查1982年发布的版本后做出的,也是出于根据此后的发展和当前的科学现状更新指南的愿望。经过该机构和公众审查后,修订后的指南将于1991年发布。修订后的指南包括一组初始测试(沙门氏菌试验、体外哺乳动物基因突变试验和体内细胞遗传学试验,后者可以是用于染色体畸变或微核形成的骨髓试验),这些测试应能对一种化学品的潜在致突变性进行充分的初步评估。可能需要进行后续测试以澄清初始测试的结果。在获得这些信息以及所有其他相关信息后,将根据证据权重对一种化学品可能存在的潜在致突变性做出决策。如果存在致突变性问题,随后将考虑进行测试以获取定性和/或定量证据,以评估与人类相关的遗传风险。此类测试范围可能从性腺暴露证据测试到显性致死测试,再到特定位点和可遗传易位试验等定量测试。致突变性评估将按照该机构的《致突变性风险评估指南》进行。致突变性数据还将根据该机构的《致癌物风险评估指南》,用于对一种化学品潜在致癌性的证据权重考量。在存在致癌性测试触发因素的情况下,在考虑现有信息后,致突变性数据可作为触发因素之一。人们认为,修订后的F分部指南将为OPP进行农药登记的致突变性测试方法提供适当且更具体的指导。它还能更清晰地说明OPP将如何着手评估和决策一种测试化学品的潜在遗传效应。(摘要截选至400字)